公开(公告)号：US20210061924A1

公开(公告)日：2021-03-04

申请号：US17069349

申请日：2020-10-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Hartmut Duefel ,  Alfred Engel ,  Frank Kroner ,  Thomas Meier ,  Sandra Rutz ,  Michael Schraeml ,  Gloria Tabares ,  Ulrike Kurtkaya ,  Boris Pinchuk ,  Christina Zimmermann

IPC: C07K16/40 ,  G01N33/543

Abstract: The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1.

公开(公告)号：US20210199659A1

公开(公告)日：2021-07-01

申请号：US17186163

申请日：2021-02-26

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Vinzent Rolny ,  Sandra Rutz ,  David Morgenstern ,  Boris Pinchuk ,  Christina Zimmermann ,  Martin Klammer ,  Franziska Sonner

IPC: G01N33/573 ,  G01N33/574

Abstract: The present disclosure relates to the finding that thymidine kinase 1 (TK-1) represents a valuable biomarker in a method for determining a Prognostic Index (PI) for risk stratification of a patient with aggressive B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL), to the use of TK-1 in such PI and to a PI comprising the marker TK-1.

公开(公告)号：US20250043024A1

公开(公告)日：2025-02-06

申请号：US18772484

申请日：2024-07-15

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Hartmut Duefel ,  Alfred Engel ,  Frank Kroner ,  Thomas Meier ,  Sandra Rutz ,  Michael Schraeml ,  Gloria Tabares ,  Ulrike Kurtkaya ,  Boris Pinchuk ,  Christina Zimmermann

IPC: C07K16/40 ,  G01N33/543

Abstract: The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1

公开(公告)号：US12077600B2

公开(公告)日：2024-09-03

申请号：US17069349

申请日：2020-10-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Hartmut Duefel ,  Alfred Engel ,  Frank Kroner ,  Thomas Meier ,  Sandra Rutz ,  Michael Schraeml ,  Gloria Tabares ,  Ulrike Kurtkaya ,  Boris Pinchuk ,  Christina Zimmermann

IPC: G01N31/00 ,  C07K16/40 ,  G01N33/53 ,  G01N33/543

CPC classification number: C07K16/40 ,  G01N33/54326 ,  C07K2317/92

Abstract: The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1.

公开(公告)号：US20180292410A1

公开(公告)日：2018-10-11

申请号：US16008550

申请日：2018-06-14

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Farshid Dayyani ,  Friedemann Krause ,  Achim Escherich ,  Birgit Wehnl ,  Ying He ,  Vinzent Rolny ,  Sandra Rutz ,  Thomas Muley ,  Felix Herth ,  Julia Riedlinger

IPC: G01N33/574

Abstract: The present disclosure relates to a method of detecting a relapse of a lung adenocarcinoma in an individual based on marker human epididymis protein 4 (HE4) and optionally Cytokeratin-19 fragments (Cyfra21-1) as well as the use of a marker in the in vitro assessment of a relapse of a lung adenocarcinoma.

公开(公告)号：US20180231570A1

公开(公告)日：2018-08-16

申请号：US15943104

申请日：2018-04-02

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Andrea Horsch ,  Birgit Klapperich ,  Dirk Block ,  Alfred Engel ,  Johann Karl ,  Rosemarie Kientsch-Engel ,  Ekaterina Manuilova ,  Christina Rabe ,  Sandra Rutz ,  Monika Soukupova ,  Ursula-Henrike Wienhues-Thelen ,  Peter Kastner ,  Edelgard Anna Kaiser

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/68 ,  G01N33/74 ,  G01N2333/47 ,  G01N2333/8139 ,  G01N2800/347 ,  G01N2800/50

Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.

公开(公告)号：US20160245827A1

公开(公告)日：2016-08-25

申请号：US15144147

申请日：2016-05-02

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Hendrik Huedig ,  Rosemarie Kientsch-Engel ,  Sandra Rutz

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/53 ,  G01N2333/47 ,  G01N2800/347 ,  G01N2800/50

Abstract: Systems and methods for diagnosing acute kidney injury following an acute event or surgical intervention, based on assessing the biomarker L-FABP. Also, systems and methods for predicting the risk of an individual to suffer from a kidney injury after an acute event or surgical intervention in the future.

Abstract translation: 基于评估生物标志物L-FABP，在急性事件或外科手术后诊断急性肾损伤的系统和方法。 另外，用于预测未来急性事件或外科手术后个体遭受肾损伤的风险的系统和方法。